Skip to main content
    C

    Crispr Therapeutics AG (CRSP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $51.52
    +1.30 (+2.59%)

    Market Cap: $4.84B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    +79.10%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.05
    Range$-1.50 - $-0.46
    17 analysts
    EPS Revisions
    9
    0
    7d
    9
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.18+11.0%
    60d ago$-1.06+0.3%
    30d ago$-1.05-0.2%
    7d ago$-1.05-0.2%
    Current$-1.05
    Revenue Consensus
    $17M
    Range$0 - $77M
    15 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.98
    Range$-2.37 - $0.28
    18 analysts
    Revenue Consensus
    $13M
    Range$-16580350 - $136M
    17 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.98---
    Sep 26EST
    		-$-1.05---
    Jun 26
    Reported Aug 3
    		$-0.94$-1.10+14.55%Beat+27.1%
    Mar 26
    Reported May 4
    		$-1.28$-1.23-4.07%Miss+19.0%
    Dec 25
    Reported Feb 12
    		$-1.37$-1.23-11.38%Miss-211.4%
    Sep 25
    Reported Nov 10
    		$-1.17$-1.29+9.30%Beat-15.8%
    Jun 25
    Reported Aug 4
    		$-1.29$-1.40+7.86%Beat+13.4%
    Mar 25
    Reported May 6
    		$-1.58$-1.28-23.44%Miss-10.5%
    Dec 24
    Reported Feb 11
    		$-0.44N/A+62.89%Beat-140.0%
    Sep 24
    Reported Nov 5
    		$-1.01$-1.40+27.86%Beat+28.4%
    Jun 24
    Reported Aug 5
    		$-1.49$-1.43-4.20%Miss-52.0%
    Mar 24
    Reported May 8
    		$-1.43$-1.33-7.52%Miss-113.4%
    Dec 23
    Reported Feb 21
    		$1.10$0.05+2100.00%Beat+178.0%
    Sep 23
    Reported Nov 6
    		$-1.41$-1.95+27.69%Beat+37.1%
    Jun 23
    Reported Aug 7
    		$-0.98N/A+53.33%Beat+59.2%
    Mar 23
    Reported May 8
    		$-0.67N/A+59.15%Beat+71.1%
    Dec 22
    Reported Feb 21
    		$-1.41$-2.30+38.70%Beat+23.4%
    Sep 22
    Reported Nov 1
    		$-2.24$-2.24+0.00%Beat-34.1%
    Jun 22
    Reported Aug 8
    		$-2.40$-2.21-8.60%Miss-125.4%
    Mar 22
    Reported May 9
    		$-2.32$-1.97-17.77%Miss-53.6%
    Dec 21
    Reported Feb 15
    		$-1.84$-1.78-3.37%Miss-22.7%
    Sep 21
    Reported Nov 3
    		$-1.67$-1.76+5.11%Beat-26.5%
    Jun 21
    Reported Jul 29
    		$9.44$3.12+202.56%Beat+826.2%
    Mar 21
    Reported Apr 27
    		$-1.51$-1.47-2.72%Miss-31.3%
    Dec 20
    Reported Feb 16
    		$-1.50$-1.27-18.11%Miss-394.1%
    Sep 20
    Reported Oct 28
    		$-1.32$-1.19-10.92%Miss-155.0%
    Jun 20
    Reported Jul 27
    		$-1.30$-0.99-31.31%Miss-28.7%
    Mar 20
    Reported Apr 28
    		$-1.15$-1.04-10.58%Miss-23.7%
    Dec 19
    Reported Feb 12
    		$0.51$-0.63+180.95%Beat+155.4%
    Sep 19
    Reported Oct 28
    		$2.40$1.79+34.08%Beat+324.3%
    Jun 19
    Reported Jul 29
    		$-1.01$-0.90-12.22%Miss-23.2%
    Mar 19
    Reported Apr 29
    		$-0.93$-0.90-3.33%Miss-50.0%
    Dec 18
    Reported Feb 25
    		$-0.92$-0.78-17.95%Miss-27158.8%
    Sep 18
    Reported Nov 7
    		$-1.07$-0.74-44.59%Miss-72.6%
    Jun 18
    Reported Aug 7
    		$-0.82$-0.64-28.13%Miss-46.4%
    Mar 18
    Reported May 8
    		$-0.62$-0.67+7.46%Beat-14.8%
    Dec 17
    Reported Mar 8
    		$0.00N/A+100.51%Beat-99.8%
    Sep 17
    Reported Nov 8
    		$-0.62$-0.60-3.33%Miss-
    Jun 17
    Reported Aug 10
    		$-0.56$-0.62+9.68%Beat-
    Mar 17
    Reported May 11
    		$-0.54$-0.65+16.92%Beat-
    Dec 16
    Reported Mar 10
    		$1.42$-0.49+389.80%Beat-

    Key Metrics

    Valuation
    P/E Ratio-10.82EV/EBITDAN/A
    Price/FCF-13.39xFCF Yield-7.47%
    Profitability
    Profit Margin0.00%Operating Margin-1128.00%
    ROE-26.10%ROIC-19.21%
    Financial Health
    Debt/Equity0.34xInterest CoverageN/A
    Current Ratio17.85xQuick Ratio17.85x
    Trading Statistics
    Beta1.76Avg Volume1.82M
    52-Week High$75.0652-Week Low$44.12

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$52.63
    SMA 20$54.34
    SMA 50$54.99
    SMA 200$53.13
    EMA 10$52.25
    EMA 20$53.34
    EMA 50$53.97
    EMA 200$53.37

    MACD

    Line: -1.11Signal: -0.63Hist: -0.49

    ADX

    ADX: 15.1+DI: 20.6-DI: 19.5

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down96.0
    PSAR$57.94

    Bollinger Bands

    Upper Band$59.63
    Lower Band$49.05
    %B Position1946%(Upper)
    Band Width0.23

    RSI (14-Day)

    Neutral
    44.1

    Momentum Oscillators

    Stoch %K12.1
    Stoch %D12.6
    Williams %R-77.8
    ROC (10d)-7.1%
    Momentum-3.92
    CCI (20d)-102.9
    MFI (14d)38.8

    Volatility Measures

    ATR (14d)$2.85(5.5%)
    StdDev (20d)2.64
    Hist Vol50.1%(High)

    Volume Flow

    VWAP$51.22
    OBV31.1M
    AD Line-10.7M
    CMF (20d)-0.244

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio0.8x
    VWMA (20d)$54.47

    Pivot Points

    R3$52.90
    R2$51.84
    R1$51.03
    Pivot Point$49.97
    S1$49.16
    S2$48.10
    S3$47.29

    Advanced Oscillators

    TSI-11.26
    Ultimate Osc39.6
    KST-46.55

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$10.18M$1.46M$864,000$889,000$892,000$865,000$35.69M$602,000$517,000$504,000$201.21M$0
    Cost of Revenue$0$0$59.36M$0$0$0$4.15M$0$0$0$20.00M$0
    Gross Profit$10.18M$1.46M$864,000$889,000$892,000$865,000$35.69M$602,000$517,000$504,000$201.21M$0
    Operating Expenses$127.45M$131.71M$155.63M$132.95M$230.22M$149.29M$100.28M$110.73M$151.78M$141.09M$131.62M$132.41M
    R&D$69.63M$68.57M$83.53M$58.90M$166.15M$72.48M$71.74M$82.16M$80.17M$76.17M$95.14M$90.70M
    SG&A$17.55M$17.18M$18.40M$16.93M$18.92M$19.30M$18.12M$17.42M$19.48M$17.95M$16.48M$18.29M
    Operating Income$-117,269,000$-130,248,000$-154,764,000$-132,059,000$-229,324,000$-148,424,000$-64,589,000$-110,130,000$-151,260,000$-140,587,000$69.58M$-132,411,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-90,194,000$-122,092,000$-129,999,000$-105,822,000$-207,257,000$-134,887,000$-36,611,000$-85,066,000$-125,121,000$-115,867,000$89.58M$-111,740,000
    Income Tax Expense$960,000$839,000$614,000$619,000$1.29M$1.11M$700,000$876,000$1.29M$724,000$233,000$412,000
    Net Income$-91,154,000$-122,931,000$-130,613,000$-106,441,000$-208,549,000$-135,996,000$-37,311,000$-85,942,000$-126,408,000$-116,591,000$89.35M$-112,152,000
    EBITDA$-85,914,000$-117,773,000$-124,338,000$-101,389,000$-202,608,000$-130,151,000$-31,769,000$-80,327,000$-120,276,000$-111,034,000$94.48M$-106,815,000
    EBIT$-90,194,000$-122,092,000$-129,999,000$-105,822,000$-207,257,000$-134,887,000$-36,611,000$-85,066,000$-125,121,000$-115,867,000$89.58M$-111,740,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CRSP

    News

    CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 1,040 Shares of Company Stock

    CRISPR Therapeutics General Counsel James Kasinger sold 1,040 shares of the company's stock for $51,230.40 to cover tax withholding obligations related to vested equity awards. After the sale...

    MarketBeat•10/15/26•Neutral

    Form 4 CRISPR Therapeutics AG: Samarth Kulkarni (Director, CEO) For: 13 October

    This article reports on a Form 4 filing for CRISPR Therapeutics AG, indicating an insider transaction by Samarth Kulkarni...

    Investing.com India•10/15/26•Neutral

    CRSP Initiated Coverage By UBS -- Rating Set to Neutral with $52

    UBS has initiated coverage on CRISPR Therapeutics (CRSP) with a "Neutral" rating and a price target of $52.00, reflecting a cautious outlook. GuruFocus indicates CRSP is significantly overvalued by 193.1%...

    GuruFocus•10/15/26•Somewhat-Bearish

    Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 4,098 Shares of Stock

    CRISPR Therapeutics CEO Samarth Kulkarni sold 4,098 shares of the company's stock for approximately $201,867, primarily to cover tax obligations from vested equity awards. The sale reduced his holdings by 1.55%...

    MarketBeat•10/15/26•Neutral

    Tax withholding required CRISPR Therapeutics (CRSP) counsel to sell shares at $49.26 each.

    James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics (CRSP), sold 1,040 common shares at $49.26 each on October 14...

    Stock Titan•10/15/26•Neutral

    CRSP Valuation and Fair Value

    P/E
    -10.8x
    Forward P/E
    23.4x
    P/FCF
    -13.4x
    PEG
    -0.2x
    P/B
    2.8x
    See GNG's fair value

    CRSP Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -1128.0%
    Net margin
    0.0%
    ROIC
    -19.2%
    ROE
    -26.1%
    FCF margin
    -2772.7%
    FCF yield
    -7.5%

    CRSP Competitors

    CompanyTicker
    Grifols SA ADRGRFS
    Scholar Rock Holding CorpSRRK
    Cogent Biosciences IncCOGT
    Concentra Group Holdings Parent, Inc.CON
    Terns Pharmaceuticals IncTERN
    Lifestance Health Group IncLFST
    Travere Therapeutics IncTVTX
    Option Care Health IncOPCH

    Sector: Healthcare

    CRSP Analyst Ratings

    Consensus
    Buy
    Analysts
    22
    Strong Buy
    5
    Buy
    8
    Hold
    9
    Sell
    0
    Strong Sell
    0

    CRSP Bull Case vs Bear Case

    Bull case

    • CRSP grew quarterly revenue 1041.0% year over year.

    CRSP Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    10.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.05
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    9 up, 2 down

    Frequently Asked Questions About CRSP

    Does CRSP pay dividends?

    Crispr Therapeutics AG (CRSP) does not currently pay a regular dividend.

    What is CRSP's market cap?

    Crispr Therapeutics AG (CRSP) has a market capitalization of $4.84B with a current stock price of $51.52.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In